Core Insights - Huadong Medicine's subsidiary, Jiangdong Company, received acceptance for the marketing application of Semaglutide injection for blood sugar control in adults with type 2 diabetes [1] - The clinical trial application for Semaglutide's weight management indication was approved in September 2024, with the Phase III trial completed in December 2024 [1] - Semaglutide is recognized for its significant market potential due to its effective blood sugar and weight management capabilities [2] Industry Overview - The global diabetes market is experiencing substantial growth, with the number of adults with diabetes increasing from approximately 200 million in 1990 to 828 million in 2022 [4] - In China, the number of adult diabetes patients reached about 148 million in 2022, accounting for 18% of the global total, with a high untreated rate of 52.7% [4] - The diabetes treatment market is expected to grow as clinical diagnosis and treatment rates improve [4] Company Developments - Huadong Medicine has a comprehensive pipeline of over 20 commercialized and in-development products targeting various diabetes treatment mechanisms, including GLP-1 receptor agonists [5] - The company’s Semaglutide injection demonstrated comparable efficacy and safety to Novo Nordisk's control drug in Phase III trials, with slightly lower adverse event rates [3] - Huadong Medicine is advancing multiple innovative products, including oral small molecule GLP-1 receptor agonists and dual-target agonists, with ongoing clinical trials [6][7] Market Position - Huadong Medicine is positioned as a strong competitor in the diabetes treatment sector, leveraging its extensive GLP-1 product pipeline and research capabilities [7] - The company aims to become a leading player in the GLP-1 market, capitalizing on its comprehensive product offerings and competitive advantages [7]

证券代码：000963 证券简称：华东医药 公告编号：2025-010 华东医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年2月20日，华东医药股份有限公司（以下简称"公司"）全 资子公司杭州中美华东制药有限公司（以下简称"中美华东"）收到国 家药品监督管理局（NMPA）签发的《受理通知书》（受理号： CXSS2500030），由中美华东申报的德谷胰岛素注射液（研发代码： HJY-36）用于治疗成人2型糖尿病的上市许可申请获得受理。现将有 关详情公告如下： 一、该药物基本信息内容 药物名称：德谷胰岛素注射液 申请事项：境内生产药品注册上市许可 注册分类：治疗用生物制品3.3类 规格：3 ml: 300 单位（笔芯） 申报适应症：用于治疗成人 2 型糖尿病 申请人：杭州中美华东制药有限公司 结论：根据《中华人民共和国行政许可法》第三十二条的规定， 经审查，决定予以受理。 二、该药物研发及注册情况 德谷胰岛素是长效胰岛素类似物，具有独特的分子结构及作用机 第 1 页 共 4 页 制，作用时间延 ...